You're asking about a compound that's a bit of a mouthful! Let's break it down:
**2-(3,4-dimethoxyphenyl)-4-quinolinecarboxylic acid (2-oxo-3-oxolanyl) ester** is a complex molecule with several components:
* **2-(3,4-dimethoxyphenyl)-4-quinolinecarboxylic acid:** This is the base molecule.
* **quinoline:** A nitrogen-containing heterocyclic compound (like a ring with a nitrogen atom in it).
* **carboxylic acid:** A functional group with a -COOH at the 4-position on the quinoline.
* **(3,4-dimethoxyphenyl):** A benzene ring substituted with two methoxy groups (-OCH3) at the 3 and 4 positions.
* **(2-oxo-3-oxolanyl) ester:** This describes the part of the molecule attached to the carboxylic acid.
* **ester:** A functional group where a carbon atom is double-bonded to an oxygen and single-bonded to another oxygen, which is then linked to an alkyl group.
* **(2-oxo-3-oxolanyl):** A specific 5-membered ring containing a carbonyl group (C=O) at position 2.
**Now, why is this compound important for research?**
The exact significance depends on the specific research area. However, this molecule likely holds interest because it combines several features often associated with biological activity:
* **Quinoline:** Quinoline derivatives are frequently found in medicinal chemistry as they exhibit various pharmacological properties, such as anti-inflammatory, anti-bacterial, and anti-cancer activities.
* **Carboxylic acid:** This functional group often contributes to the binding of molecules to proteins and enzymes, which is essential for many biological processes.
* **(3,4-dimethoxyphenyl) group:** This group can influence the molecule's properties, such as its solubility and interaction with biological targets.
* **Ester:** Esters can be useful for modifying the properties of a molecule, like its stability or ability to cross cell membranes.
**To understand the exact research relevance, you'd need more context. For instance:**
* **What specific research area is this molecule being investigated in?** (e.g., drug discovery, materials science, etc.)
* **What are the intended applications of this molecule?** (e.g., treating a specific disease, developing a new material, etc.)
Without this information, it's difficult to pinpoint the exact importance of this molecule.
Let me know if you can provide more details, and I'd be happy to delve further into its specific research significance!
ID Source | ID |
---|---|
PubMed CID | 2999765 |
CHEMBL ID | 1601002 |
CHEBI ID | 107689 |
Synonym |
---|
smr000062971 |
MLS000081723 , |
OPREA1_112485 |
CHEBI:107689 |
MLS002634077 |
(2-oxooxolan-3-yl) 2-(3,4-dimethoxyphenyl)quinoline-4-carboxylate |
HMS2338G03 |
(2-oxidanylideneoxolan-3-yl) 2-(3,4-dimethoxyphenyl)quinoline-4-carboxylate |
cid_2999765 |
2-(3,4-dimethoxyphenyl)-4-quinolinecarboxylic acid (2-oxo-3-oxolanyl) ester |
2-(3,4-dimethoxyphenyl)cinchoninic acid (2-ketotetrahydrofuran-3-yl) ester |
bdbm79429 |
sr-01000043172 |
SR-01000043172-1 |
CHEMBL1601002 |
Q27186014 |
Z18933392 |
AKOS033650636 |
Class | Description |
---|---|
quinolines | A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 16.1654 | 0.0447 | 17.8581 | 100.0000 | AID485294; AID485341 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 50.1187 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 39.8107 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 13.4591 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 31.6228 | 0.0013 | 18.0743 | 39.8107 | AID926 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 63.5144 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 39.8107 | 0.0398 | 16.7842 | 39.8107 | AID995 |
ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 10.0000 | 0.6561 | 9.4520 | 25.1189 | AID927 |
snurportin-1 | Homo sapiens (human) | Potency | 63.5144 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 56.2341 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 31.6228 | 0.0003 | 11.4484 | 31.6228 | AID900 |
Caspase-7 | Homo sapiens (human) | Potency | 31.6228 | 3.9811 | 18.5856 | 31.6228 | AID889 |
Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 10.0000 | 1.5849 | 13.0043 | 25.1189 | AID927 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 3.5481 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
caspase-3 isoform a preproprotein | Homo sapiens (human) | EC50 (µMol) | 85.3180 | 7.8940 | 7.8940 | 7.8940 | AID504328 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |